Context Therapeutics Inc. - Common Stock (NQ:CNTX)

0.3218 -0.0147 (-4.37%)

Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Context Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

12 Health Care Stocks Moving In Friday's After-Market Session ↗

August 04, 2023

Via Benzinga

Context Therapeutics to Participate in Two August 2023 Investor Conferences

August 01, 2023

From Context Therapeutics Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

July 19, 2023

Via Benzinga

ASCO 2023 – Claudin 6 Makes A Splash In Ovarian Cancer ↗

June 08, 2023

This year’s 2023 American Society of Clinical Oncology Annual Meeting (ASCO 2023) provided a surprising amount of clinical data relevant to biopharma investors.

Via Benzinga

Traders Insights: These Biotech Stocks On Radar: VSTM, SNTX, CGEN, SONN

June 05, 2023

Via AB Newswire

Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

June 05, 2023

Gainers Sono Group N.V. (NYSE: SEV) shares surged 152.7% to $0.4367. Sono Group applied to Insolvency Court of Munich, Germany, to permit opening of self-administration proceeding.

Via Benzinga

Context Therapeutics Reports First Quarter 2023 Operating and Financial Results

May 10, 2023

From Context Therapeutics Inc.

Via GlobeNewswire

Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A Difference

April 18, 2023

Via ACCESSWIRE

Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ: CNTX) Plans To Make A Difference ↗

April 14, 2023

Context Therapeutics Inc. (NASDAQ: CNTX) is a biopharmaceutical company committed to advancing medicines for solid tumors by harnessing novel and innovative treatment targets such as Claudin 6...

Via Benzinga

Context Therapeutics to Participate in Two April 2023 Investor Conferences

April 03, 2023

From Context Therapeutics Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2023 ↗

March 23, 2023

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

March 23, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

March 23, 2023

We're starting off the day with a look at the biggest pre-market stock movers traders need to know about on Thursday morning!

Via InvestorPlace

Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates

March 22, 2023

From Context Therapeutics Inc.

Via GlobeNewswire

Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

March 15, 2023

Context to host webinar with AACR presenter on Monday, April 17, 2023, at 4:30 p.m. ET

From Context Therapeutics Inc.

Via GlobeNewswire

$7M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Buying ↗

February 22, 2023

The Dow Jones closed lower by around 700 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Context Therapeutics And 3 Other Stocks Under $2 Insiders Are Aggressively Buying ↗

February 14, 2023

The Dow Jones closed higher by more than 370 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Insiders Buying AmeriServ Financial And 2 Other Penny Stocks ↗

February 07, 2023

The Dow Jones dropped by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in...

Via Benzinga

Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer

February 06, 2023

From Context Therapeutics Inc.

Via GlobeNewswire

Why TransCode Therapeutics Shares Are Trading Higher By 42%; Here Are 20 Stocks Moving Premarket ↗

February 01, 2023

Gainers

Via Benzinga

Tesla, Amazon, Apple, Context Therapeutics, Snap: Why These 5 Stocks Are Drawing Investors' Attention Today ↗

January 31, 2023

Major Wall Street indices closed over 1% higher on Tuesday, led by upbeat corporate earnings and expectations that the Federal Reserve will slow down its rate hike pace as the centr

Via Benzinga

Dow Surges Over 200 Points; Pfizer Issues Weak Forecast ↗

January 31, 2023

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 200 points on Tuesday. The Dow traded up 0.63% to 33,931.13 while the NASDAQ rose 1.20% to 11,529.99. The S&P...

Via Benzinga

Why Context Therapeutics (CNTX) Shares Are Seeing Blue Skies ↗

January 31, 2023

Context Therapeutics Inc (NASDAQ: CNTX) shares are trading higher by 60.32% to $1.10 Tuesday afternoon after the company announced its clinical trial collaborator, Stemline Therapeutics, received...

Via Benzinga

Why AppTech Payments Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

January 31, 2023

Gainers

Via Benzinga

Dow Turns Higher; Nasdaq Jumps 100 Points ↗

January 31, 2023

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Tuesday. The Dow traded up 0.19% to 33,781.23 while the NASDAQ rose 0.90% to 11,496.13. The S&P...

Via Benzinga

Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer

January 31, 2023

From Context Therapeutics Inc.

Via GlobeNewswire

$1 Million Bet On Motorsport Games? Check Out These 4 Penny Stocks Insiders Are Buying ↗

January 31, 2023

The Nasdaq dropped more than 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in...

Via Benzinga

Context Therapeutics And 3 Other Stocks Under $1 Insiders Are Aggressively Buying ↗

January 24, 2023

The Dow Jones closed higher by more than 250 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Myomo, Enzo Biochem And These 2 Stocks Under $2 Insiders Are Aggressively Buying ↗

January 19, 2023

The Dow Jones closed lower by more than 600 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers

January 09, 2023

From Context Therapeutics Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.